Puma Biotechnology (NASDAQ:PBYI) Releases Earnings Results, Beats Expectations By $0.15 EPS

Puma Biotechnology (NASDAQ:PBYI) posted its earnings results on Thursday. The biopharmaceutical company reported $0.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.15, FiscalAI reports. Puma Biotechnology had a return on equity of 21.34% and a net margin of 11.50%.The business had revenue of $56.50 million during the quarter, compared to analysts’ expectations of $53.00 million.

Here are the key takeaways from Puma Biotechnology’s conference call:

• NERLYNX revenue and demand improved: Q2 net product revenue rose to $53.6 million from $42.0 million in Q1 and $49.2 million a year ago, while U.S. demand increased 8% sequentially and 11% year over year. Management raised full-year 2026 net product revenue guidance to $205–$209 million.
• Puma reported Q2 GAAP net income of $8.2 million, reversing a $3.8 million loss in Q1, and raised full-year net income guidance to $17–$20 million. The company also made its final $11.1 million loan payment and is now debt-free.
• Alisertib development is progressing, with ALISCA-Breast1 enrollment being narrowed to the 40 mg and 50 mg dose groups and ALISCA-Lung1 now enrolling at 70 mg twice daily. Puma expects to start the combination trial ALISCA-Lung02 in Q3 and provide additional trial data in 2027.
• New prescriptions for NERLYNX declined 6% sequentially, and the company expects higher 2026 R&D spending, up 34%–37% year over year, as clinical trials advance. Q3 net income guidance of $2–$2.5 million is substantially below Q2’s result.
• Full-year royalty guidance was reduced to $19–$22 million from $20–$23 million, partly reflecting a possible late-2026 or 2027 reduction in China royalties if generic NERLYNX reaches a specified market-share threshold.

Puma Biotechnology Stock Performance

PBYI traded up $0.79 on Friday, reaching $8.91. The company had a trading volume of 683,217 shares, compared to its average volume of 315,645. The stock has a market cap of $453.51 million, a P/E ratio of 17.13 and a beta of 1.22. Puma Biotechnology has a fifty-two week low of $3.05 and a fifty-two week high of $9.40. The company’s fifty day moving average is $7.80 and its 200 day moving average is $7.18.

Insider Activity at Puma Biotechnology

In other news, insider Douglas M. Hunt sold 8,460 shares of the stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $8.26, for a total transaction of $69,879.60. Following the transaction, the insider owned 196,841 shares in the company, valued at approximately $1,625,906.66. This trade represents a 4.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jay M. Moyes sold 22,000 shares of Puma Biotechnology stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $7.22, for a total value of $158,840.00. Following the sale, the director directly owned 58,322 shares of the company’s stock, valued at approximately $421,084.84. The trade was a 27.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 132,028 shares of company stock valued at $1,006,711. Insiders own 22.20% of the company’s stock.

Institutional Investors Weigh In On Puma Biotechnology

Institutional investors have recently modified their holdings of the business. Russell Investments Group Ltd. increased its position in Puma Biotechnology by 4,823,365.0% during the third quarter. Russell Investments Group Ltd. now owns 964,693 shares of the biopharmaceutical company’s stock worth $5,123,000 after acquiring an additional 964,673 shares during the period. Goldman Sachs Group Inc. boosted its holdings in Puma Biotechnology by 238.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 793,962 shares of the biopharmaceutical company’s stock valued at $4,724,000 after purchasing an additional 559,345 shares during the period. AQR Capital Management LLC boosted its holdings in Puma Biotechnology by 410.1% in the 4th quarter. AQR Capital Management LLC now owns 666,605 shares of the biopharmaceutical company’s stock valued at $3,966,000 after purchasing an additional 535,933 shares during the period. Bridgeway Capital Management LLC grew its position in shares of Puma Biotechnology by 78.4% during the 4th quarter. Bridgeway Capital Management LLC now owns 773,485 shares of the biopharmaceutical company’s stock worth $4,602,000 after purchasing an additional 339,924 shares in the last quarter. Finally, O Shaughnessy Asset Management LLC grew its position in shares of Puma Biotechnology by 35.3% during the 4th quarter. O Shaughnessy Asset Management LLC now owns 1,120,329 shares of the biopharmaceutical company’s stock worth $6,666,000 after purchasing an additional 292,108 shares in the last quarter. Institutional investors own 61.29% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on PBYI. TD Cowen upped their price objective on Puma Biotechnology from $5.00 to $6.00 and gave the stock a “hold” rating in a research report on Friday. Weiss Ratings lowered Puma Biotechnology from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Finally, Wall Street Zen cut Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 16th. Two analysts have rated the stock with a Hold rating, According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $6.00.

Key Stories Impacting Puma Biotechnology

Here are the key news stories impacting Puma Biotechnology this week:

• Positive Sentiment: Second-quarter results exceeded expectations. Puma reported earnings of $0.19 per share, above the $0.04 consensus estimate, while revenue reached $56.5 million versus expectations of $53.0 million. Profitability included a 10.69% net margin and 20.30% return on equity. Puma Biotechnology Q2 2026 earnings results
• Positive Sentiment: Full-year 2026 revenue guidance was raised. Puma now expects revenue of $224 million to $231 million, above the approximately $222.5 million analyst consensus. Rising Nerlynx sales and planned milestones for the alisertib program provide additional potential catalysts. PBYI Q2 earnings and raised guidance
• Neutral Sentiment: Management’s outlook was mixed for the next quarter. Third-quarter revenue guidance of $56 million to $59 million is slightly below the $59.4 million consensus estimate, suggesting that near-term growth may be more modest despite the improved full-year outlook. Puma Biotech Q2 earnings and revenue results
• Negative Sentiment: TD Cowen remains cautious. The firm raised its price target from $5 to $6 but maintained a “hold” rating. The revised target still implies roughly 32.7% downside from the referenced $8.91 share price, potentially weighing on investor sentiment after the recent advance. TD Cowen raises Puma Biotechnology price target

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.